NCT05030415

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

A Proof of Concept, Non-randomized, One Center Study to Explore the Safety and Efficacy of 16 Weeks of Treatment With Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University of New Mexico · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).

Detailed description

A proof of concept, non-randomized, one center study to explore the safety and efficacy of 16 weeks of treatment with ixekizumab in adult patients with lichen planus. The total study period will consist of 24 weeks including a 2 week screening/washout, 16 weeks of active therapy and 8 weeks of follow up.

Conditions

• Lichen Planus Scalp
• Lichen Planus
• Lichen Planopilaris

Interventions

Type	Name	Description
DRUG	Ixekizumab Auto-Injector	160 mg week 0 followed by 80 mg every two weeks

Timeline

• Start date: 2021-08-12
• Primary completion: 2024-03-25
• Completion: 2024-03-25
• First posted: 2021-09-01
• Last updated: 2024-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study